Denali therapeutics announces new dnl343 (eif2b agonist) phase 1b data in als to be presented at the upcoming aan annual meeting

South san francisco, calif., april 10, 2023 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that new data from the 28-day treatment period of the phase 1b study of dnl343 in participants with amyotrophic lateral sclerosis (als) will be presented at the 75th annual meeting of the american academy of neurology (aan), which will be held april 22-27, 2023, in boston, massachusetts. dnl343 is an investigational, small molecule eif2b activator designed to cross the bbb with the potential of preventing or slowing als disease progression. the dnl343 abstract is available here on the aan conference website. a pdf of the poster presentation will be made available on denali's website under the events section here after the aan poster session begins at 11:45 a.m. edt on april 25, 2023. as previously announced, dnl343 has been selected to enter the phase 2/3 healey als platform trial; denali expects that recruiting will begin in mid 2023.
DNLI Ratings Summary
DNLI Quant Ranking